2020
Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia 2020, 35: 1643-1660. PMID: 32868875, PMCID: PMC7917159, DOI: 10.1038/s41375-020-01020-4.Peer-Reviewed Original ResearchConceptsOverall response ratePEG-IFNPolycythemia veraEssential thrombocythemiaHematologic responsePV patientsResponse rateSystematic reviewMeta-regression analysis resultsSafe long-term treatmentPartial hematologic responseSafety of interferonInterferon-alpha therapyLong-term treatmentRandom-effects modelMeta-regression analysisWeb of ScienceTreatment discontinuationCochrane RegistryAdverse eventsComplete responsePartial responsePrimary outcomeThromboembolic complicationsClinical trials
2019
Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials
Holleck JL, Merchant N, Gunderson CG. Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal Of General Internal Medicine 2019, 34: 1018-1024. PMID: 30937668, PMCID: PMC6544709, DOI: 10.1007/s11606-019-04899-7.Peer-Reviewed Original ResearchConceptsSymptom-triggered therapyDuration of therapyAlcohol withdrawal syndromeBenzodiazepine doseWithdrawal syndromeTrial of patientsLow-risk patientsGeneral hospital settingRandomized Controlled TrialsRisk of biasTerms of mortalitySystematic literature searchStrength of evidenceBenzodiazepine dosageDose therapyMedication classesCochrane RegistryCochrane riskDose regimensAlcohol withdrawalBias toolControlled TrialsDose scheduleResultsSix studiesI2 statistic
2018
Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov
Bothwell LE, Avorn J, Khan NF, Kesselheim AS. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. BMJ Open 2018, 8: e018320. PMID: 29440155, PMCID: PMC5829673, DOI: 10.1136/bmjopen-2017-018320.Peer-Reviewed Original ResearchConceptsIndependent data monitoring committeeData monitoring committeeDesign clinical trialEuropean Medicines AgencyClinical trialsInterim analysisAdaptive design clinical trialsPhase I/II trialPhase II/IIIAdaptive trialsControlled clinical trialsBasic study characteristicsWeb of ScienceII trialCochrane RegistryInclusion criteriaDose-finding designDrug AdministrationMedicines AgencyStudy characteristicsSuch trialsMonitoring committeeAdaptive design featuresPhase ITrialsObesity in the Workplace
Yarborough CM, Brethauer S, Burton WN, Fabius RJ, Hymel P, Kothari S, Kushner RF, Morton JM, Mueller K, Pronk NP, Roslin MS, Sarwer DB, Svazas B, Harris JS, Ash GI, Stark JT, Dreger M, Ording J. Obesity in the Workplace. Journal Of Occupational And Environmental Medicine 2018, 60: 97-107. PMID: 29303847, PMCID: PMC6034693, DOI: 10.1097/jom.0000000000001220.Peer-Reviewed Original ResearchConceptsImpact of obesityLifestyle modificationBariatric surgeryCochrane RegistryAppropriate patientsSurgical interventionClinical trialsHealth outcomesObesityInsurance coverageHealth costsInterventionMore researchComprehensive literature reviewLiterature reviewPatientsSurgeryRegistryCINAHLPubMedTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply